In short. Treating with no baseline means accepting risk for an unmeasurable gain. The alternatives begin with sun protection and with waiting.
Key points
- Risk is normally accepted for a benefit that can be observed.
- Here it is accepted for a benefit that cannot be, which makes the category unlike almost any other in medicine.
- Naming the trade is not an argument against making it; it is what makes it a decision rather than a default.
The risks in this subject have an unusual shape, and it is worth setting out plainly because the category depends on it not being noticed.
Risk accepted for an unmeasurable gain
Every intervention here carries labelled risks. In ordinary practice those risks are accepted in exchange for improving something that exists and can be seen: a hollow filled, a pigment patch reduced, a line softened. In a prevention programme they are accepted in exchange for a change that did not occur, and because no comparison was made, neither the person nor anyone else will ever be able to say whether the treatment was responsible. That is the structural feature of the category, and it is not a rhetorical point: it is what a person is agreeing to.
The clinical risks
An injectable carries bruising and swelling that settle, nodules and lumps that may need treatment, asymmetry, infection and, rarely, vascular occlusion that can cause skin loss or visual loss. A device carries burn, pigment change and scarring, and pigment change is more likely in some skin types than others. A topical retinoid causes irritation and photosensitivity, particularly in the first weeks. None of those is reduced by the fact that the person has no findings, and a maintenance programme that repeats treatment over years accumulates them rather than spreading them out in any meaningful sense.
The trade is unusual, and worth naming
Risk is normally accepted for a benefit that can be observed. Here it is accepted for a benefit that cannot be, which makes the category unlike almost any other in medicine. Naming the trade is not an argument against making it; it is what makes it a decision rather than a default.
The alternatives
Sun protection and not smoking are the measures with substantial evidence behind them, they need no clinical intervention, and they can be started at any age with a benefit. A person doing those two things is doing more, in evidence terms, than a person buying a preventive programme, and the comparison is not close. Waiting is the second alternative and it is more useful than it sounds: a face with no findings is a face with no baseline, so revisiting the question when a specific finding appears converts an unmeasurable proposition into one that can be photographed, treated and compared. Where a finding does appear, the options are described on the other guides in this cluster, each with its own evidence position.
When to have something assessed rather than prevented
- A mole or patch that is changing in size, shape or colour.
- A lesion that bleeds, itches or will not heal.
- Blistering, crusting or pigment change that follows a device treatment.
None of those is a prevention question, and all three are reasons to see a clinician rather than to buy anything.
Frequently asked questions
What is the central risk of a prevention programme?
That labelled risks are accepted now for a benefit that cannot be measured, now or later. In ordinary practice the risks buy an improvement in something that exists. Here they buy an avoided change that nobody will be able to attribute to the treatment, because no comparison was made.
What are the clinical risks?
The labelled risks of whatever is used, and they apply whether or not a finding exists: bruising, nodules, asymmetry, infection and rarely vascular occlusion for an injectable; burn, pigment change and scarring for a device; irritation and photosensitivity for a topical. Repetition in a maintenance programme accumulates them.
What is the alternative to a prevention programme?
Sun protection and not smoking, which are the measures with evidence behind them and need no clinical intervention. Waiting is the second: a face with no findings has no baseline, so nothing can be measured, and revisiting the question when a specific finding appears makes it a better-defined decision with something that can be photographed and compared.
Risks & Limitations
- A face with no findings has no measurable baseline, so a preventive benefit cannot be demonstrated while the risks of treatment remain real.
- Nothing is approved with a preventive indication for facial ageing; approvals are for treating a change that is already present.
- Sun protection and not smoking are the only preventive measures with substantial support, and neither needs a clinical treatment.
- Treating early or maintaining a result is not prevention, and repeated treatment accumulates the labelled risks.
- A claim that nothing could contradict is a claim that cannot be supported either, and this category's claims are of that kind.
When to Seek Care
- A mole or patch that is changing in size, shape or colour — have it assessed by a clinician.
- A lesion that bleeds, itches or will not heal — have it assessed by a clinician.
- Blistering, crusting or pigment change that follows a device treatment — have it assessed by a clinician.
- Severe pain, dusky or mottled skin, or a change in vision after an injection — seek emergency care immediately.
References & Further Reading
- World Health Organization (WHO) — ultraviolet radiation and skin cancer prevention guidance
- U.S. Food and Drug Administration (FDA) — approved products and devices and their labelled indications
- National Medical Products Administration (NMPA, China) — approved products and their indications
- Cochrane Library — systematic reviews of photoprotection and topical treatments
- Chinese Medical Association Dermatology Branch — clinical guidance
This page is a review of published evidence and regulation, not medical advice, and it does not cite individual studies. It is not a booking page and it does not recommend a treatment, for or against. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.